-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 JygpdM+e3ZgB40HxV4CgPg2llU3fn8Dn8cRKBOBePKtg6MN6vLcX98L7cHp9FK3q
 sKWxuNnegN71NrlYAfJ39Q==

<SEC-DOCUMENT>0001157523-04-011712.txt : 20041222
<SEC-HEADER>0001157523-04-011712.hdr.sgml : 20041222
<ACCEPTANCE-DATETIME>20041222164140
ACCESSION NUMBER:		0001157523-04-011712
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20041222
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041222
DATE AS OF CHANGE:		20041222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENE LOGIC INC
		CENTRAL INDEX KEY:			0001043914
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				061411336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23317
		FILM NUMBER:		041221284

	BUSINESS ADDRESS:	
		STREET 1:		708 QUINCE ORCHARD
		STREET 2:		ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		3019871700

	MAIL ADDRESS:	
		STREET 1:		708 QUINCE ORCHARD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a4789759.txt
<DESCRIPTION>GENE LOGIC INC.
<TEXT>
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                 ---------------

                                    FORM 8-K

                                 CURRENT REPORT


                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                Date of Report (Date of earliest event reported)
                      December 22, 2004 (December 16, 2004)



                                 GENE LOGIC INC.
             (Exact name of registrant as specified in its charter)



        DELAWARE                   0-23317                 06-1411336
- ------------------------   -------------------------   -----------------------
(State of Incorporation)    (Commission File Number)        (IRS Employer
                                                        Identification Number)



                             610 Professional Drive
                          Gaithersburg, Maryland 20879
                    (Address of principal executive offices)


                                 (301) 987-1700
              (Registrant's telephone number, including area code)


                                       NA
          (Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================


<PAGE>


SECTION 1.  REGISTRANT'S BUSINESS AND OPERATIONS

Item 1.01.        Entry Into a Definitive Material Agreement

         The Company's Board of Directors has approved certain increases in
non-employee Director compensation, effective January 1, 2005. In addition, in
connection with the establishment of a non-executive Chairman position, the
Board of Directors recently established compensation for the position and for
the current Chairman, effective November 9, 2004, the date of his election to
office.

         The attached Exhibit 10.6a, incorporated herein by reference, sets
forth the new compensation.



Item 9.01.        Financial Statements and Exhibits

(c)          Exhibits

Exhibit Number                          Description
- --------------                  ----------------------------------------------
    10.6a                       Summary of Non-Employee Director Compensation.


<PAGE>




                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            Gene Logic Inc.


                                            By: /s/ Philip L. Rohrer, Jr.
                                            --------------------------
                                            Philip L. Rohrer, Jr.
                                            Chief Financial Officer



Dated:  December 22, 2004




<PAGE>



                                  EXHIBIT INDEX


Exhibit Number                              Description
- --------------                              -----------
10.6a                                       Summary of Non-Employee Director
                                            Compensation.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>a4789759ex106.txt
<DESCRIPTION>EXHIBIT 10.6(A)
<TEXT>
                                    GENELOGIC

EXHIBIT 10.6a

<TABLE>
<CAPTION>

                  Summary of Non-Employee Director Compensation
                  ---------------------------------------------


<S>                                                                    <C>      <C>
Annual Retainer (Directors other than Chairman)                        $25,000
Board Chairman Annual Retainer                                         $50,000

Committee Chairman Annual Retainer
         Audit Committee                                               $10,000
         Compensation Committee                                        $10,000
         Nominating and Corporate Governance Committee                 $ 5,000

Board Meeting Fee                                                      $ 1,500  per meeting

Committee Meeting Fee (if not held with regular Board mtg.)            $ 1,000

Initial Director Stock Option Grant upon election (#)                   30,000*
Initial Chairman Stock Option Grant upon election (#)                   60,000 (less shares from initial
                                                                                grant upon prior election
                                                                                to Board)**

Annual Director Stock Option Grant (#)                                  15,000***
Annual Chairman Stock Option Grant (#)                                  20,000***
</TABLE>

- -----------------

*    Subject to sufficient plan shares, exercise price at fair market value on
     date of grant, vesting in four equal annual increments commencing on first
     anniversary of date of grant or upon a change of control and similar
     events, ten year term, terminates 12 mos. after no longer a Director or 18
     mos. in case of death.

**   Subject to sufficient plan shares, exercise price at fair market value on
     date of grant, vesting in three equal annual increments commencing on first
     anniversary of date of grant or upon a change of control and similar
     events, ten year term, terminates 12 mos. after no longer a Director or 18
     mos. in case of death.

***  Subject to sufficient plan shares and stockholder approval of the Chairman
     grant; exercise price at fair market value on date of grant, vesting in
     full on first anniversary of grant date or upon a change of control and
     similar events, terminates 12 mos. after no longer a Director or 18 mos. in
     case of death.

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
